Skip to main content

JS Link, Inc. (KOSDAQ:127120)

South Korea flag South Korea · Delayed Price · Currency is KRW
42,300
-1,400 (-3.20%)
At close: Apr 28, 2026
369.48%
Market Cap 1.46T
Revenue (ttm) 19.32B
Net Income (ttm) -16.45B
Shares Out 34.50M
EPS (ttm) -601.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 183,561
Average Volume 185,768
Open 43,200
Previous Close 43,700
Day's Range 40,400 - 43,400
52-Week Range 7,800 - 49,900
Beta 0.58
RSI 51.49
Earnings Date May 14, 2026

About JS Link

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additio... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 84
Stock Exchange KOSDAQ
Ticker Symbol 127120
Full Company Profile

Financial Performance

In 2025, JS Link's revenue was 19.32 billion, an increase of 21.43% compared to the previous year's 15.91 billion. Losses were -16.45 billion, 52.2% more than in 2024.

Financial Statements

News

There is no news available yet.